VividVisions. Legal performance marketing Log in

Depo-Provera meningioma leads
for plaintiff firms.

Claims allege that long-term use of the Depo-Provera contraceptive injection increased the risk of intracranial meningioma, a brain tumor, without adequate warning. We screen claimants against your firm’s criteria.

Discuss a campaign
Serving law firms nationwide

Summary of public information for law firms. Not legal advice.

Delivery models

Three ways to receive Depo-Provera cases.

The right model depends on your intake capacity and acquisition economics.

At the inquiry

Qualified leads

Claimants screened against your firm’s Depo-Provera criteria, delivered with their responses to your intake team or CRM.

For teams that handle follow-up and conversion.

Discuss qualified leads

At the conversation

Warm transfers

Screened claimants connected directly with your intake team during agreed hours and within your delivery caps.

For teams ready to take a live call.

How live transfers work

At the retainer

Signed retainers

For select programs, acquisition structured around qualified, completed e-signed retainers.

For firms seeking a retained-client model.

About retainer programs

The litigation · October 2026

What firms
should know now.

Litigation moves quickly. We confirm current status, and whether a program fits your firm’s strategy, before launch.

Sources
  1. 2025

    Federal cases centralized

    Federal Depo-Provera cases were centralized as MDL No. 3140 in the Northern District of Florida before Judge M. Casey Rodgers.

  2. Dec 2025

    FDA label change

    The FDA approved a label change for Depo-Provera that adds a warning about meningioma.

  3. Jun 2026

    Settlement in principle

    Judge Rodgers entered an order confirming that plaintiffs’ leadership and Pfizer reached a global settlement in principle. Terms had not been made public at our October 2026 review.

Screening

Questions built
from your criteria.

These are the areas Depo-Provera screening typically covers. The exact questions and thresholds come from your firm.

Talk through your criteria
  1. Use history

    When injections began and how long, or how many, Depo-Provera injections were received.

  2. Diagnosis

    A meningioma diagnosis, its date and how it was identified.

  3. Treatment

    Surgery, radiation or ongoing monitoring, and the records available.

  4. Representation

    Whether the claimant already has an attorney for the claim.

Questions

What firms ask
about Depo-Provera.

Answers specific to your program are part of the first conversation.

Is the Depo-Provera settlement final?

As of our October 2026 review, the June 2026 agreement was in principle and its terms had not been made public. Whether new claims fit your docket is your firm’s decision; we confirm program availability before launch.

What injury is involved?

Intracranial meningioma, a typically non-cancerous brain tumor, alleged to be linked to long-term use of the injection.

Can leads include consent documentation?

Where a program requires it, leads can be delivered with a TrustedForm or Jornaya certificate. Call recordings for transfers depend on program support and applicable consent requirements.

Sources

Public sources for this summary.

Summary of public information as of October 2026, for law firms evaluating case acquisition. It is not legal advice, and litigation status changes.

Start a conversation

Let’s look at
your next campaign.

Send the practice area, criteria and volume you have in mind. We’ll talk through the right delivery model and a sensible starting point.

Book a 30-minute intro call

Your inquiry is emailed to our team. This website does not store form entries. Please share business requirements only.

Campaign inquiry

Ready for your email app.

Review the details below. Nothing has been sent.

Open email app

If your email app doesn’t open, copy the inquiry and email info@vividvisions.marketing.

This website

Website privacy

When you send a campaign inquiry, the details you enter are emailed to the VividVisions team. This website does not store form entries. If sending fails, you can instead pass the inquiry to your own email application and choose whether to send it.

This website uses Vercel Web Analytics to count page views and see which pages are read. It does not use cookies or advertising pixels and does not identify individual visitors. Its fonts are served with the website. Hosting and email providers may process technical or message data under their own policies.

This notice covers this corporate website. Consumer campaign pages and claimant forms require separate disclosures appropriate to their data collection and consent processes.

Questions: info@vividvisions.marketing